VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Stock Comparison

AstraZeneca PLC vs Compagnie Financiere Richemont SA

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AstraZeneca PLC

AZN · London Stock Exchange

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryGB
Data as of2026-01-02
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.

View AZN analysis

Compagnie Financiere Richemont SA

CFR · SIX Swiss Exchange

Market cap (USD)$101.1B
Gross margin (TTM)66.8%
Operating margin (TTM)21.3%
Net margin (TTM)14.8%
SectorConsumer
IndustryLuxury Goods
CountryCH
Data as of2025-12-30
Moat score
84/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Compagnie Financiere Richemont SA's moat claims, evidence, and risks.

View CFR analysis

Comparison highlights

  • Moat score gap: Compagnie Financiere Richemont SA leads (84 / 100 vs 71 / 100 for AstraZeneca PLC).
  • Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Compagnie Financiere Richemont SA has 3 segments (71.6% in Jewellery Maisons).
  • Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Compagnie Financiere Richemont SA has 4 across 2.

Primary market context

AstraZeneca PLC

Oncology

Market

Innovator oncology therapeutics (branded prescription medicines)

Geography

Global

Customer

Hospitals, oncology clinics, payers

Role

Innovator biopharmaceutical company

Revenue share

41%

Compagnie Financiere Richemont SA

Jewellery Maisons

Market

Luxury jewellery (branded fine jewellery & high jewellery)

Geography

Global

Customer

Affluent and high-net-worth consumers

Role

Brand owner, manufacturer and direct-to-client retailer

Revenue share

71.6%

Side-by-side metrics

AstraZeneca PLC
Compagnie Financiere Richemont SA
Ticker / Exchange
AZN - London Stock Exchange
CFR - SIX Swiss Exchange
Market cap (USD)
n/a
$101.1B
Gross margin (TTM)
n/a
66.8%
Operating margin (TTM)
n/a
21.3%
Net margin (TTM)
n/a
14.8%
Sector
Healthcare
Consumer
Industry
n/a
Luxury Goods
HQ country
GB
CH
Primary segment
Oncology
Jewellery Maisons
Market structure
Oligopoly
Oligopoly
Market share
n/a
30%-55% (implied)
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
71 / 100
84 / 100
Moat domains
Legal, Supply, Demand
Demand, Supply
Last update
2026-01-02
2025-12-30

Moat coverage

Shared moat types

Capex Knowhow ScaleBrand Trust

AstraZeneca PLC strengths

Regulated Standards PipeIP Choke Point

Compagnie Financiere Richemont SA strengths

Distribution ControlReputation Reviews

Segment mix

AstraZeneca PLC segments

Full profile >

Oncology

Oligopoly

41%

Cardiovascular, Renal and Metabolism (CVRM)

Competitive

23%

Respiratory & Immunology (R&I)

Oligopoly

15%

Vaccines & Immune Therapies (V&I)

Oligopoly

3%

Rare Disease

Oligopoly

16%

Other Medicines

Competitive

2%

Compagnie Financiere Richemont SA segments

Full profile >

Jewellery Maisons

Oligopoly

71.6%

Specialist Watchmakers

Oligopoly

15.3%

Other (Fashion & Accessories, Watchfinder, ancillary)

Competitive

13%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.